- Myelosuppressive chemotherapy - To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
- Acute myeloid leukemia (AML) - For reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML.
- Severe chronic neutropenia - For chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g., fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital, cyclic or idiopathic neutropenia.
- Bone marrow transplant - To reduce the duration of neutropenia and neutropenia-related clinical sequelae, eg febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemo-therapy followed by marrow transplantation.
- Peripheral blood progenitor cell collection - For mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.
- Neupogen: Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)
Coverage of drugs is first determined by the member’s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document.